Author: Lo, Chien-Hsien; Wang, Yu-Hsun; Tsai, Chin-Feng; Chan, Kuei-Chuan; Li, Li-Ching; Lo, Tse-Hsien; Wei, James Cheng-Chung; Su, Chun-Hung
Title: Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study Cord-id: m8n53knq Document date: 2021_5_20
ID: m8n53knq
Snippet: OBJECTIVES: Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with systemic lupus erythematosus. METHODS: This was a nested case-control study using data from the Longitudinal Health Insurance Database of Taiwan. A conditional logistic regress
Document: OBJECTIVES: Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with systemic lupus erythematosus. METHODS: This was a nested case-control study using data from the Longitudinal Health Insurance Database of Taiwan. A conditional logistic regression model was used to analyse differences in the risk of arrhythmia between systemic lupus erythematosus patients with and without hydroxychloroquine treatment after controlling for related variables. RESULTS: A total of 2499 patients with newly diagnosed systemic lupus erythematosus were identified (81% females), of whom 251 were enrolled in the new-onset arrhythmia group (mean age 50.4 years) and 251 in the non-arrhythmia group (mean age 49.1 years). There was no significantly increased risk of cardiac arrhythmia (adjusted odds ratio = 1.49, 95% confidence interval: 0.98–2.25) or ventricular arrhythmia (adjusted odds ratio = 1.02, 95% confidence interval: 0.19–5.41) between the patients with and without hydroxychloroquine treatment. In addition, there were no significant differences in the risk of arrhythmia between those receiving hydroxychloroquine treatment for <180 days or ≥180 days, with a drug adherence rate of <50% or ≥50%, and receiving a daily dose of <400 mg or ≥400 mg. CONCLUSION: In patients with systemic lupus erythematosus, hydroxychloroquine treatment did not significantly increase the risk of cardiac arrhythmia or life-threatening ventricular arrhythmia regardless of the different hydroxychloroquine treatment duration, drug adherence rate, or daily dose.
Search related documents:
Co phrase search for related documents- additional analysis and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adherence rate and logistic regression: 1, 2, 3, 4
- adherence rate and long follow: 1
- adherence rate and long follow period: 1
- adherence rate and lupus erythematosus: 1
- logistic regression analysis and long duration: 1, 2, 3, 4
- logistic regression analysis and long follow: 1, 2, 3, 4, 5, 6, 7, 8, 9
- logistic regression analysis and long term treatment: 1, 2, 3
- logistic regression analysis and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
- logistic regression and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- logistic regression and long follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- logistic regression and long follow period: 1, 2
- logistic regression and long term treatment: 1, 2, 3, 4, 5
- logistic regression and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- logistic regression model and long duration: 1, 2, 3
- logistic regression model and long follow: 1, 2, 3, 4
- logistic regression model and lupus erythematosus: 1, 2
- long follow and lupus erythematosus: 1, 2, 3
- long term treatment and lupus erythematosus: 1, 2
Co phrase search for related documents, hyperlinks ordered by date